The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are
calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive …

Vascular calcification (VC) is highly prevalent in aging, diabetes mellitus, and chronic kidney
disease (CKD). VC is a strong predictor of cardiovascular morbidity and mortality in the CKD …

In the course of chronic kidney disease (CKD), alterations in the bone-vascular axis
augment the risk of bone loss, fractures, vascular and soft tissue calcification, left ventricular …

Introduction: Severe osteoporosis represents a disease of high mortality and morbidity.
Recognition of what constitutes and causes severe osteoporosis and aggressive …

Context: Sclerostin, a Wnt antagonist produced by osteocytes, regulates osteoblast activity
and is a well-established key player in bone turnover. Recent data indicate that the Wnt …

Patients with chronic kidney disease (CKD) are at increased risk of osteoporosis and
vascular calcification. Bone demineralization and vascular mineralization go often hand in …

Overall and cardiovascular mortality in patients with chronic kidney disease (CKD) is greatly
increased, without obvious current effective treatments. Mineral and bone disorder (MBD) is …

The aim of this study was to evaluate the effect of anti-tumor necrosis factor α (anti-TNF-α)
therapy in combination with methotrexate on bone remodeling and osteoclastogenesis in …

At the early stage of chronic kidney disease (CKD), the systemic mineral metabolism and
bone composition start to change. This alteration is known as chronic kidney disease …

Background Derangements in bone metabolism and vascular calcification (VC) substantially
contribute to the accelerated cardiovascular morbidity and mortality in chronic kidney …